<?xml version="1.0" encoding="UTF-8"?>
<ref id="B47-vaccines-08-00531">
 <label>47.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Leitão</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Cartaxeiro</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Coelho</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Cruz</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Parkhouse</surname>
    <given-names>R.M.E.</given-names>
   </name>
   <name>
    <surname>Portugal</surname>
    <given-names>F.C.</given-names>
   </name>
   <name>
    <surname>Vigário</surname>
    <given-names>J.D.</given-names>
   </name>
   <name>
    <surname>Martins</surname>
    <given-names>C.L.V.</given-names>
   </name>
  </person-group>
  <article-title>The non-haemadsorbing African swine fever virus isolate ASFV/NH/P68 provides a model for defining the protective anti-virus immune response</article-title>
  <source>J. Gen. Virol.</source>
  <year>2001</year>
  <volume>82</volume>
  <fpage>513</fpage>
  <lpage>523</lpage>
  <pub-id pub-id-type="doi">10.1099/0022-1317-82-3-513</pub-id>
  <pub-id pub-id-type="pmid">11172092</pub-id>
 </element-citation>
</ref>
